The detection of serum organic acid metabolites by LC/MC technology has potential clinical application value in the identification of prostatitis, prostatic hyperplasia, and prostate cancer, which can reduce patients’ puncture pain and compensate for the deficiency of PSA in the diagnosis of prostate diseases (Supplemental Material, Figure 7). The gene discussed is KLK3; the disease is benign prostatic hyperplasia.